Compound class:
Synthetic organic
Comment: TXA709 is an orally bioavailable prodrug of TXA707 (PubChem: 90135655), a benzamide antibacterial compound that inhibits the essential and conserved prokaryotic cell division protein FtsZ [3]. TXA709 is under clinical development, as a combination therapy with synergistic drug partners, for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) [1-2].
|
|